Tauriello et al. recently demonstrated that inhibition of TGFβ signaling with galunisertib can contribute to sustained anti-tumor immunity and PD-1/PD-L1 responsiveness in preclinical animal models [29]. This evidence concerns the gene TGFB1 and neoplasm.